Keyword trend analysis identified the emergence of newer GLP-1 agonists, such as tirzepatide and semaglutide, as well as a growing focus on topics like ‘healthy obesity’ and chronic kidney disease. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.